New Cellular Therapy for HIV in World's First Engineered T Cell Receptor Trial
Wednesday, October 7, 2009 - 15:14
in Health & Medicine
(PhysOrg.com) -- Researchers at Adaptimmune Limited and the University of Pennsylvania School of Medicine, today announced the approval of an Investigational New Drug (IND) application from the US Food and Drug Administration (FDA) and opening for enrollment of the first ever study using patients` cells carrying an engineered T cell receptor to treat HIV (SL9 HA-GAG-TCR). The trial may have important implications in the development of new treatments for HIV potentially slowing - or even preventing - the onset of AIDS.
